REMICADE® is a biologic anti-TNF (tumour necrosis factor-alpha) medication used for the treatment of several chronic autoimmune and inflammatory conditions. Each vial contains 100 mg of infliximab — a monoclonal antibody that helps control harmful inflammation by targeting and neutralizing TNF-α in the body. REMICADE® is administered intravenously in a clinical setting under professional supervision.

Key Features & Indications

• Effective treatment option for:
  • Moderate to severe rheumatoid arthritis (with methotrexate)
  • Moderate to severe Crohn’s disease (adults and pediatric)
  • Ulcerative colitis (adults and pediatric)
  • Ankylosing spondylitis
  • Psoriatic arthritis
  • Moderate to severe plaque psoriasis

• Can help reduce symptoms, improve physical function, and promote mucosal healing in inflammatory bowel disease

• Designed for patients who do not respond adequately to conventional therapies

How It Works
Infliximab specifically binds to TNF-α — a key driver of chronic inflammation — preventing it from attaching to receptors and causing immune-mediated tissue damage. By reducing inflammatory activity, REMICADE® helps protect joints, improve intestinal health, and support overall disease control.

Ideal Candidates

• Patients diagnosed with approved autoimmune conditions who require biologic infusion therapy

• Individuals with inadequate response to first-line treatments

• Cases where regular clinical monitoring is preferred

Administration & Packaging

• Supplied as 100 mg powder in a single-use glass vial

• Reconstituted and diluted for intravenous infusion

• Dosing is weight-based and scheduled at induction and maintenance intervals

• Infusions must take place in a clinical environment equipped for monitoring

Possible Side Effects & Considerations

• Increased susceptibility to infection due to immune suppression — screening (e.g., TB, hepatitis) required

• Infusion-related reactions can occur; pre-medication may be recommended

• Rare risks include certain malignancies, demyelinating disorders, and liver function abnormalities

• Live vaccines should generally be avoided during treatment

• Continuous clinician assessment is necessary to evaluate safety and response